Takeaways
- Estrogen-based hormone therapy did not consistently reduce anxiety or depression in perimenopausal or postmenopausal women.
- Modest benefits were observed among symptomatic women within a few years of their final menstrual period, particularly with oral formulations.
- Researchers emphasized that treatment response varies by menopause stage, symptom severity, and delivery route, underscoring the need for individualized therapy.
Anxiety and depression are among the most common psychological symptoms reported during the menopause transition. Both conditions are influenced by hormonal fluctuations, but the degree to which estrogen-based hormone therapy alleviates these symptoms remains unclear. Findings from two systematic reviews, presented at The Menopause Society’s 2025 Annual Meeting in Orlando, Florida, highlight inconsistent effects of estrogen-based therapy on anxiety and depression among perimenopausal and early postmenopausal women.1,2
Study overview
Researchers from McMaster University and the University of Toronto conducted two separate systematic reviews and meta-analyses to examine the influence of estrogen-based hormone therapy on mental health symptoms during midlife. One review focused on anxiety, while the second investigated depression.
For the anxiety analysis, seven studies were identified, including randomized controlled trials, cohort studies, and case-control studies evaluating estrogen-based therapy via oral or transdermal routes. Collectively, these studies enrolled more than 1,200 perimenopausal or postmenopausal women, with additional observational studies encompassing roughly 175,000 midlife participants.
For the depression analysis, 23 studies published between 2001 and 2024 were reviewed, spanning a range of designs and sample sizes—from small clinical trials of 30 to 50 participants to population-based studies involving more than 800,000 women. Most intervention studies followed participants for 8 to 24 weeks, though some extended up to 4 years.
Findings and patterns
In both reviews, researchers found that estrogen-based therapy produced variable outcomes depending on factors such as menopause stage, route of administration, and baseline symptom severity.
In the anxiety review, estrogen therapy did not consistently reduce anxiety symptoms in midlife women. Modest benefits were observed among perimenopausal or early postmenopausal participants, especially those within a few years of their final menstrual period and with prominent anxiety symptoms at baseline. Oral estrogen appeared to show the most favorable, though limited, effects.